ContraFect Corp. (CFRXQ) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerContraFect Corp. (CFRXQ) trades at $0.00001. ContraFect Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening and drug-resistant infectious diseases. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for CFRXQ: CFRXQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
ContraFect Corp. (CFRXQ) Healthcare & Pipeline Overview
ContraFect Corporation, now in Chapter 7 liquidation, focused on developing lysins and antibodies to combat drug-resistant infections, including Staphylococcus aureus and Pseudomonas aeruginosa. Its lead candidate, Exebacase, targeted Staphylococcus aureus, while other programs addressed infections related to biofilms and gram-negative pathogens. The company's future is uncertain due to its bankruptcy filing.
What Is the Investment Thesis for CFRXQ?
ContraFect Corporation's Chapter 7 liquidation filing on December 4, 2023, fundamentally alters any prior investment thesis. The company's pipeline, including Exebacase in Phase III trials for Staphylococcus aureus infections and CF-370 in Phase 1 for Pseudomonas aeruginosa, no longer presents a viable investment opportunity. The company's market capitalization of $0.00B reflects its current state. Any potential value recovery for shareholders is highly speculative and contingent on the bankruptcy proceedings.
Based on FMP financials and quantitative analysis
CFRXQ Key Highlights
ContraFect Corporation filed for Chapter 7 liquidation on December 4, 2023, effectively halting its operations.
- The company's lead program, Exebacase, was in Phase III clinical trials targeting Staphylococcus aureus infections before the bankruptcy filing.
- ContraFect was developing CF-370, an anti-bacterial therapeutic candidate, in Phase 1 clinical trials for Pseudomonas aeruginosa infections.
- The company's market capitalization is $0.00B, reflecting its current financial distress.
- ContraFect had a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens.
Who Are CFRXQ's Competitors?
CFRXQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CFRXQ's Key Strengths?
Proprietary lysin technology platform.
- Clinical-stage therapeutic candidates targeting drug-resistant infections.
- License agreement with The Rockefeller University.
- Focus on addressing unmet needs in the anti-infectives market.
What Are CFRXQ's Weaknesses?
Chapter 7 bankruptcy filing.
- Limited financial resources.
- Dependence on external funding.
- High regulatory hurdles for drug approval.
What Are the Key Risks for CFRXQ?
Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Chapter 7 bankruptcy proceedings.
- Complete loss of investment for shareholders.
- Delisting from the OTC market.
- Legal and regulatory challenges.
- Inability to revive the company's operations.
What Threats Does CFRXQ Face?
- Competition from larger pharmaceutical companies.
- Failure to obtain regulatory approval for its therapeutic candidates.
- Patent expirations.
- Changes in healthcare regulations.
What Are CFRXQ's Competitive Advantages?
- Proprietary lysin technology platform for developing novel anti-infective therapies.
- Patent protection for its lead therapeutic candidates, including Exebacase and CF-370.
- Clinical data supporting the efficacy and safety of its therapeutic candidates.
What Does CFRXQ Do?
ContraFect Corporation, established in 2008 and headquartered in Yonkers, New York, was a clinical-stage biotechnology company dedicated to discovering and developing therapeutic protein and antibody products aimed at treating life-threatening and drug-resistant infectious diseases. The company's primary focus was on addressing critical unmet needs in the treatment of severe infections, particularly those caused by antibiotic-resistant bacteria. Its lead program, Exebacase, a novel lysin, had reached Phase III clinical trials and was designed to target Staphylococcus aureus, a common cause of serious infections. In addition to Exebacase, ContraFect was also developing CF-370, an investigational anti-bacterial therapeutic candidate in Phase 1 clinical trials, intended to treat Pseudomonas aeruginosa infections, including ventilator-associated pneumonia, bloodstream infections, complicated urinary tract infections, and surgical site infections. The company also had CF-296 in preclinical development, targeting osteomyelitis and prosthetic joint infections (PJI). Furthermore, ContraFect explored the use of Exebacase for treating persistent bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) in COVID-19 patients. ContraFect's approach involved the development of engineered lysins, such as CF-296, to combat invasive infections caused by Staphylococcus aureus, including biofilm-related infections associated with prosthetic joints, indwelling devices, and osteomyelitis. The company also held a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. However, on December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware, casting doubt on the future of its programs.
What Products and Services Does CFRXQ Offer?
- Discovered and developed therapeutic protein and antibody products.
- Focused on treating life-threatening and drug-resistant infectious diseases.
- Developed Exebacase, a lysin in Phase III clinical trials for Staphylococcus aureus infections.
- Developed CF-370, an investigational anti-bacterial therapeutic candidate in Phase 1 clinical trials for Pseudomonas aeruginosa infections.
- Developed CF-296 for osteomyelitis and prosthetic joint infections (PJI).
- Explored Exebacase for treating persistent bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) in COVID-19 patients.
- Developed engineered lysins for treating invasive infections caused by Staphylococcus aureus, including biofilm-related infections.
- Maintained a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens.
How Does CFRXQ Make Money?
- Focused on discovering and developing novel anti-infective therapies.
- Out-licensed or partnered its therapeutic candidates with larger pharmaceutical companies for commercialization.
- Relied on venture capital and public offerings to fund its research and development activities.
What Industry Does CFRXQ Operate In?
ContraFect Corporation operated within the biotechnology industry, which is characterized by high risk and high reward. Companies in this sector focus on developing innovative therapies for various diseases. The competitive landscape is intense, with numerous companies vying for market share. ContraFect's focus on anti-infectives, particularly lysins, placed it in a niche segment of the broader biotechnology market. However, the company's bankruptcy underscores the challenges faced by smaller biotech firms in securing funding and navigating the regulatory approval process. The bankruptcy of ContraFect highlights the volatility and risk inherent in the biotechnology industry.
Who Are CFRXQ's Key Customers?
- Hospitals and healthcare providers treating patients with severe bacterial infections.
- Patients suffering from life-threatening and drug-resistant infections.
- Pharmaceutical companies seeking to expand their anti-infective portfolios through licensing or partnerships.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
ContraFect Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Yonkers, US. The company is led by CEO Roger J. Pomerantz. CFRXQ has traded publicly since 2014.
Financial Health
ContraFect Corp.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Earnings Track Record
ContraFect Corp. has beaten Wall Street's EPS estimate in 4 of its last 7 reported quarters — more hits than misses. Reported results have landed about 7.8% above estimates on average.
Forward Outlook
Wall Street analysts project ContraFect Corp. revenue of about $36.0M for fiscal 2026, with EPS near $-2.14.
CFRXQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
CFRXQ Latest News
No recent news available for CFRXQ.
CFRXQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CFRXQ.
Price Targets
Wall Street price target analysis for CFRXQ.
CFRXQ MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CFRXQ; grades run from A+ (80-100) to F (below 30).
CFRXQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ContraFect Corporation's stock did not meet the requirements for the higher tiers (OTCQX and OTCQB). Companies in this tier often have limited financial disclosure, may be undergoing financial distress (as is the case with ContraFect's Chapter 7 filing), and may not be current in their reporting obligations. Investing in OTC Other stocks carries significant risks due to the lack of regulation and transparency compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- High risk of fraud and manipulation.
- Illiquidity and difficulty in trading shares.
- Potential for delisting and loss of investment.
- Bankruptcy proceedings and uncertain future.
- Verify the company's financial statements, if available.
- Research the company's management team and their track record.
- Assess the company's legal and regulatory compliance.
- Understand the company's business model and competitive landscape.
- Evaluate the company's risk factors and potential liabilities.
- Consult with a financial advisor before investing.
- Be aware of the risks associated with OTC investments.
- Prior history as a NASDAQ-listed company (before delisting).
- Development of therapeutic candidates in clinical trials.
- License agreement with The Rockefeller University.
- Focus on addressing unmet needs in the anti-infectives market.
Common Questions About CFRXQ (Healthcare)
What are the main risks for CFRXQ?
The primary risk for CFRXQ is the ongoing Chapter 7 bankruptcy proceedings, which pose a significant threat to shareholders. The company's assets are being liquidated, and there is a high probability that shareholders will experience a complete loss of their investment.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change due to the bankruptcy proceedings.
- The company's future is highly uncertain.